The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“Antagonists of the lysophosphatidic acid-1 receptor, a growth factor that induces CTGF and TGF-β 1 expression, are being considered as treatments for kidney fibrosis, IPF and systemic sclerosis 159,160 .”
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
“The lysophosphatidic acid receptor 1 also controls the recruitment of fibroblasts in mice with bleomycin-induced fibrosis and levels of lysophosphatidic acid are increased in the BAL fluid of people with IPF (Tager et al., 2008).”
BackgroundMechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., Sisson, T. H., Horowitz, J. C., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2014 · Cited by 874
Self-citationLPA Receptors: Subtypes and Biological Actions
Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C.-W., Mutoh, T., Lin, M.-E., Teo, S. T., Park, K. E., Mosley, A. N., et al. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 839
Self-citationFeedback amplification of fibrosis through matrix stiffening and COX-2 suppression
Liu, F., Mih, J. D., Shea, B. S., Kho, A. T., Sharif, A. S., Tager, A. M., & Tschumperlin, D. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201004082 · Cited by 810
“C57BL/6 mice (The National Cancer Institute Animal Production Program) were instilled intratracheally with 0.05 U bleomycin (Gensia Sicor Pharmaceuticals Inc.) in 50 µl sterile saline or with 50 µl sterile saline for control mice, with lung tissue harvested 14 d later (Tager et al., 2008).”
InfluentialSelf-citationTsukui, T., Sun, K.-H., Wetter, J. B., Wilson-Kanamori, J. R., Hazelwood, L. A., Henderson, N. C., Adams, T. S., Schupp, J. C., Poli, S. D., Rosas, I. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15647-5 · Cited by 765
LPA receptor signaling: pharmacology, physiology, and pathophysiology
Yung, Y. C., Stoddard, N. C., & Chun, J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046458 · Cited by 710
“Not only does LPA mediate the progression of fibrosis via cell growth, but LPA1 has also been implicated in the initiation of disease through excessive fibroblast recruitment and persistent maintenance of leaky vasculature (251).”
BackgroundSelf-citationTherapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
“The LPA receptor LPA1 is expressed on multiple cell types and plays a pathogenic role in tissue injury and fibrosis in mouse models (197, 198).”
BackgroundPathogenetic mechanisms in radiation fibrosis
Yarnold, J., & Vozenin Brotons, M.-C. (2010) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2010.09.002 · Cited by 622
“Mice deficient for LPA receptor are protected against bleomycin-induced lung fibrosis, suggesting a connection between inflammation and fibrosis [16].”
BackgroundPulmonary fibrosis: patterns and perpetrators
Noble, P. W., Barkauskas, C. E., & Jiang, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60323 · Cited by 595
“Recently, lysophosphatidic acid (LPA) has been shown to be present following lung injury, and its cognate receptor, LPAR1, is necessary for the recruitment of fibroblasts to the lung and the development of fibrosis following lung injury (55).”
Shimizu, T. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145616 · Cited by 576
Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions
Della Latta, V., Cecchettini, A., Del Ry, S., & Morales, M. A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.012 · Cited by 514
Two pathways for lysophosphatidic acid production
AOKI, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.06.005 · Cited by 448
New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis
Fernandez, I. E., & Eickelberg, O. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61144-1 · Cited by 437
Mesenchymal stem cells in fibrotic disease
El Agha, E., Kramann, R., Schneider, R. K., Li, X., Seeger, W., Humphreys, B. D., & Bellusci, S. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.011 · Cited by 430
“Furthermore, Lpa1 knockoutmiceare significantly protected against lungfibrosis (Tager et al., 2008).”
BackgroundInfluentialCytosolic phospholipase A2: physiological function and role in disease
Leslie, C. C. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r057588 · Cited by 413
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Chapman, H. A. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142225 · Cited by 412
Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis
Gasse, P., Riteau, N., Charron, S., Girre, S., Fick, L., Pétrilli, V., Tschopp, J., Lagente, V., Quesniaux, V. F. J., Ryffel, B., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1274oc · Cited by 410
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080201 · Cited by 382
Burnham, E. L., Janssen, W. J., Riches, D. W. H., Moss, M., & Downey, G. P. (2014) · European Respiratory Journal · doi:10.1183/09031936.00196412 · Cited by 365
Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
Li, Y., Jiang, D., Liang, J., Meltzer, E. B., Gray, A., Miura, R., Wogensen, L., Yamaguchi, Y., & Noble, P. W. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102510 · Cited by 382
“mouse lungs as described previously (Tager et al., 2008; Jiang et al., 2010).”
MethodUnderstanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities
Bhattacharyya, S., Wei, J., & Varga, J. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.149 · Cited by 381
“LPA induces fibroblast activation and migration, and mice with genetic deletion of the LPA receptor 1 (LPAR1) are protected from bleomycin-induced lung and skin fibrosis”
Celada, L. J., Kropski, J. A., Herazo-Maya, J. D., Luo, W., Creecy, A., Abad, A. T., Chioma, O. S., Lee, G., Hassell, N. E., Shaginurova, G. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar8356 · Cited by 363
Self-citationBioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance
Lin, M.-E., Herr, D. R., & Chun, J. (2010) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.02.002 · Cited by 363
“In a model using bleomycin to induce fibrosis in lung, Lpar1−/− mice showed decreased fibroblasts and collagen deposition [125].”
MethodSelf-citationTschumperlin, D. J., Ligresti, G., Hilscher, M. B., & Shah, V. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93561 · Cited by 330
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330
“…[many of which were noted in section II (Gardell et al., 2006)], including cancer (Mills and Moolenaar, 2003), fibrosis (Prade`re et al., 2007; Tager et al., 2008), pain (Gardell et al., 2006), obesity (Simon et al., 2005; Yea et al., 2008), and, most importantly from the standpoint of a…”
BackgroundInfluentialSelf-citationLysophospholipid receptor nomenclature review: IUPHAR Review 8
Kihara, Y., Maceyka, M., Spiegel, S., & Chun, J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12678 · Cited by 324
“Fibrosis links to LPA include in the lung, kidney, and liver (Ikeda et al., 1998; Wu and Zern, 2000; Pradere et al., 2007; 2008; Watanabe et al., 2007; Tager et al., 2008).”
BackgroundSelf-citationRole of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies
Geraldo, L. H. M., Spohr, T. C. L. D. S., Amaral, R. F. D., Fonseca, A. C. C. D., Garcia, C., Mendes, F. D. A., Freitas, C., dosSantos, M. F., & Lima, F. R. S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00367-5 · Cited by 313
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
“These include the receptor for advanced glycation end products (RAGE), which is highly expressed in alveolar epithelial type I cells and is significantly decreased in the lungs of patients with IPF.151 Decreased circulating RAGE levels correlate with declining lung function in IPF.152 Another possible biomarker assess…”
BackgroundInfluentialThe role of myofibroblasts in wound healing
Hinz, B. (2016) · Current Research in Translational Medicine · doi:10.1016/j.retram.2016.09.003 · Cited by 328
“The antagonist of the LPA1 receptor, BMS-986202 (Bristol-Myers Squibb) protects mice from experimental skin fibrosis [157,158].”
BackgroundInfluentialVarga, J., Trojanowska, M., & Kuwana, M. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000249 · Cited by 323
“Significantly, levels of LPA are elevated in patients with pulmonary fibrosis (125, 126).”
BackgroundRAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., Diefenbacher, M., Stamp, G., & Downward, J. (2013) · Cell · doi:10.1016/j.cell.2013.04.031 · Cited by 306
“LPA has been identified as a critical fibroblast chemoattractant in experimental lung fibrosis, and LPA1 receptor knockout mice are protected in this model (Tager et al., 2008).”
InfluentialModeling pulmonary fibrosis with bleomycin
Mouratis, M. A., & Aidinis, V. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac2b · Cited by 311
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308
“IPF patients have increased LPA levels [131] in their bronchoalveolar lavage fluid (BALF) (Table 3), and recently, it has been shown that LPA signalling mediates both the fibroblast recruitment and vascular leakage induced by lung injury in a bleomycin model of pulmonary fibrosis [131].”
BackgroundFibrosis—a lethal component of systemic sclerosis
Ho, Y. Y., Lagares, D., Tager, A. M., & Kapoor, M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.53 · Cited by 306
Self-citationFibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
Sakai, & Tager, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.001 · Cited by 285
Self-citationStructural basis of substrate discrimination and integrin binding by autotaxin
Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., Albers, H. M. H. G., van Meeteren, L. A., Houben, A. J. S., van Zeijl, L., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1980 · Cited by 278
Karsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A.-C., Smith, V., Adamkewicz, J. I., Christiansen, C., & Leeming, D. J. (2013) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2012.474 · Cited by 279
Cellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
The pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
“Thrombin and lysophosphatidic acid (LPA) are G-protein-coupled receptor agonists, and both of these substances have been shown to promote avb6-integrin-mediated TGF-b activation and are implicated in the development of IPF [Tager et al. 2008; Howell et al. 2002].”
BackgroundThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
TGF-β Activation and Lung Fibrosis
Tatler, A. L., & Jenkins, G. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-003aw · Cited by 263
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P. L., & Wijsenbeek, M. S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.010 · Cited by 256
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
Swaney, J., Chapman, C., Correa, L., Stebbins, K., Bundey, R., Prodanovich, P., Fagan, P., Baccei, C., Santini, A., Hutchinson, J., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00828.x · Cited by 261
“Mice lacking LPA1 receptors exhibit decreased pulmonary vascular leakage following bleomycin injury, which is believed to contribute to a reduction in lung damage (Tager et al., 2008).”
BackgroundResultInfluentialLysophospholipids and their receptors in the central nervous system
Choi, J. W., & Chun, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.015 · Cited by 255
Self-citationPulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis
Oikonomou, N., Mouratis, M.-A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D., & Aidinis, V. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0004oc · Cited by 250
Therapeutic targets in lung tissue remodelling and fibrosis
Liu, G., Philp, A. M., Corte, T., Travis, M. A., Schilter, H., Hansbro, N. G., Burns, C. J., Eapen, M. S., Sohal, S. S., Burgess, J. K., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107839 · Cited by 249
Lysoglycerophospholipids in chronic inflammatory disorders: The PLA2/LPC and ATX/LPA axes
Sevastou, I., Kaffe, E., Mouratis, M.-A., & Aidinis, V. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.019 · Cited by 241
Autotaxin--an LPA producing enzyme with diverse functions
Nakanaga, K., Hama, K., & Aoki, J. (2010) · Journal of Biochemistry · doi:10.1093/jb/mvq052 · Cited by 239
Atabai, K., Jame, S., Azhar, N., Kuo, A., Lam, M., McKleroy, W., DeHart, G., Rahman, S., Xia, D. D., Melton, A. C., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40053 · Cited by 237
Lysophosphatidic acid (LPA) and its receptors
Noguchi, K., Herr, D., Mutoh, T., & Chun, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.11.010 · Cited by 235
“3 Stress fiber formation [20] Pulmonary fibrosis [90] GPR26 Neurite retraction, cell rounding [3,20,26] Renal fibrosis [91]”
BackgroundSelf-citationAhluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
“chemoattractant activity of BAL fluid (102).”
Self-citationKnipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Self-citationThe Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis
Haak, A. J., Kostallari, E., Sicard, D., Ligresti, G., Choi, K. M., Caporarello, N., Jones, D. L., Tan, Q., Meridew, J., Diaz Espinosa, A. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6296 · Cited by 218
Self-citationLysophosphatidic acid as a lipid mediator with multiple biological actions
Aikawa, S., Hashimoto, T., Kano, K., & Aoki, J. (2015) · Journal of Biochemistry · doi:10.1093/jb/mvu077 · Cited by 214
“Hair follicle development PA-PLA1a LPA6 (22, 23, 28, 51) Vascular development ATX, LPP3 LPA1,4,6 (30, 33 36, 52) Pulmonary/renal fibrosis unidentified LPA1 (53, 54) Neuropathic pain ATX LPA1 (55, 56) Embryo implantation unidentified LPA3 (57 60) Spermatogenesis ATX, LPP1 LPA1-3 (61 64) Lysophosphatidic acid as a lipid…”
BackgroundXu, M. Y., Porte, J., Knox, A. J., Weinreb, P. H., Maher, T. M., Violette, S. M., McAnulty, R. J., Sheppard, D., & Jenkins, G. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080160 · Cited by 217
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Unifying mechanism for different fibrotic diseases
Wernig, G., Chen, S.-Y., Cui, L., Van Neste, C., Tsai, J. M., Kambham, N., Vogel, H., Natkunam, Y., Gilliland, D. G., Nolan, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621375114 · Cited by 206
“The molecular processes driving fibrogenesis are not well-understood, involving but not limited to transforming growth factor B (TGFB), platelet-derived growth factor (PDGF), connective-tissue growth factor (CTGF), vasoactive peptide, integrin signaling, and increased tissue stiffness (7, 8).”
BackgroundBoronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation
Albers, H. M. H. G., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., Schuurman, K., van Tellingen, O., Morris, A. J., Smyth, S. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001529107 · Cited by 204
Nakagawa, S., Wei, L., Song, W. M., Higashi, T., Ghoshal, S., Kim, R. S., Bian, C. B., Yamada, S., Sun, X., Venkatesh, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.11.004 · Cited by 205
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript et al., 2007; Sakai et al., 2013; Tager et al., 2008).”
BackgroundSelf-citationCrystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1
Chrencik, J. E., Roth, C. B., Terakado, M., Kurata, H., Omi, R., Kihara, Y., Warshaviak, D., Nakade, S., Asmar-Rovira, G., Mileni, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.002 · Cited by 204
“…effects on every organ system exam- ined thus far, with receptor dysregulation linked to a range of dis- ease indications including hydrocephalus (Yung et al., 2011), infertility (Ye et al., 2005), fibrosis (Tager et al., 2008), pain (Inoue et al., 2004), and cancer (Mills andMoolenaar, 2003).”
BackgroundSelf-citationNovel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
“The potential significance of this mediator in lung fibrosis has been highlighted by studies demonstrating a critical role for LPA1 activation in fibroblast recruitment and vascular leak following experimentally induced lung injury in mice (Tager et al., 2008).”
BackgroundPalmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
“ALT $ 3-5 ULN 0 (0) 0 (0) 8 (17) > 5 ULN 0 (0) 3 (7) 2 (4) AST $ 3-5 ULN 0 (0) 1 (2) 3 (6) > 5 ULN 0 (0) 1 (2) 0 (0) ALP $ 3-5 ULN 0 (0) 0 (0) 2 (4) > 5 ULN 0 (0) 0 (0) 0 (0) Total bilirubin $ 3-5 ULN 0 (0) 1 (2) 0 (0) > 5 ULN 0 (0) 1 (2) 0 (0)”
Autotaxin: structure-function and signaling
Perrakis, A., & Moolenaar, W. H. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046391 · Cited by 187
Oga, T., Matsuoka, T., Yao, C., Nonomura, K., Kitaoka, S., Sakata, D., Kita, Y., Tanizawa, K., Taguchi, Y., Chin, K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2066 · Cited by 190
“A recent study reported that lysophosphatidic acid acts on lysophosphatidic acid receptor-1 to induce fibroblast recruitment and contributes to pulmonary fibrosi”
BackgroundCellular and Molecular Mechanisms of Chronic Inflammation-Associated Organ Fibrosis
Ueha, S., Shand, F. H. W., & Matsushima, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00071 · Cited by 182
Insights into autotaxin: how to produce and present a lipid mediator
Moolenaar, W. H., & Perrakis, A. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3188 · Cited by 190
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation
Lagares, D., Busnadiego, O., García‐Fernández, R. A., Kapoor, M., Liu, S., Carter, D. E., Abraham, D., Shi‐Wen, X., Carreira, P., Fontaine, B. A., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33482 · Cited by 192
“Bronchoalveolar lavage fluid (BALF) samples for analysis of leukocyte recruitment and vascular leakage were obtained as previously reported (21).”
MethodSelf-citationLysophospholipid receptors in drug discovery
Kihara, Y., Mizuno, H., & Chun, J. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.11.020 · Cited by 189
Self-citationThe Autotaxin–LPA Axis Emerges as a Novel Regulator of Lymphocyte Homing and Inflammation
Knowlden, S., & Georas, S. N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302831 · Cited by 177
Castelino, F. V., & Varga, J. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3097 · Cited by 182
Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy
Wei, J., Bhattacharyya, S., Tourtellotte, W. G., & Varga, J. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.015 · Cited by 173
“Recently LPA was shown to induce fibroblast chemotaxis and CTGF production [54].”
BackgroundAiming drug discovery at lysophosphatidic acid targets
Tigyi, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00815.x · Cited by 170
“In several models, inhibition of the LPA1 receptor inhibits the progression of fibrosis (Pradere et al., 2007; Tager et al., 2008), but LPA-induced aVb6 integrin-mediated TGF-b activity is mediated via the LPA2 receptor (Xu et al.”
BackgroundInfluentialBiological roles of lysophosphatidic acid signaling through its production by autotaxin
Okudaira, S., Yukiura, H., & Aoki, J. (2010) · Biochimie · doi:10.1016/j.biochi.2010.04.015 · Cited by 165
Gan, X., Wang, J., Wang, C., Sommer, E., Kozasa, T., Srinivasula, S., Alessi, D., Offermanns, S., Simon, M. I., & Wu, D. (2012) · Nature Cell Biology · doi:10.1038/ncb2507 · Cited by 163
Castelino, F. V., Seiders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J., Luster, A. D., & Tager, A. M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30262 · Cited by 168
“In previous studies, we found that LPA1 expression was not required for TGF downstream signaling in fibroblasts, since increases in procollagen type I 1 chain, fibronectin, and -SMA expression induced by TGF were similar in WT and LPA1deficient mouse lung fibroblasts (3).”
InfluentialSelf-citationLipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways
Suryadevara, V., Ramchandran, R., Kamp, D. W., & Natarajan, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124257 · Cited by 165
ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis
Lagares, D., Ghassemi-Kakroodi, P., Tremblay, C., Santos, A., Probst, C. K., Franklin, A., Santos, D. M., Grasberger, P., Ahluwalia, N., Montesi, S. B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4419 · Cited by 162
“Bronchoscopies were preformed at both the Instituto Nacional de Enfermedades Respiratorias (INER), Mexico and the Massachusetts General Hospital (MGH), as previously described 38 .”
InfluentialSelf-citationRole of Sonic Hedgehog in idiopathic pulmonary fibrosis
Bolaños, A. L., Milla, C. M., Lira, J. C., Ramírez, R., Checa, M., Barrera, L., García-Alvarez, J., Carbajal, V., Becerril, C., Gaxiola, M., et al. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2012 · Cited by 160
Self-citationNovel lysophosphoplipid receptors: their structure and function
Makide, K., Uwamizu, A., Shinjo, Y., Ishiguro, J., Okutani, M., Inoue, A., & Aoki, J. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046920 · Cited by 160
Role of LPA4/p2y9/GPR23 in Negative Regulation of Cell Motility
Lee, Z., Cheng, C.-T., Zhang, H., Subler, M. A., Wu, J., Mukherjee, A., Windle, J. J., Chen, C.-K., & Fang, X. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-03-0316 · Cited by 159
“When the lpa1 knockout mice were studied under pathophysiological conditions, however, essential roles for LPA1 in the initiation of neuropathic pain and promotion of pulmonary and renal fibrosis were unraveled (Inoue et al., 2004; Pradere et al., 2007; Tager et al., 2008).”
BackgroundInfluentialLysophospholipid Mediators in Health and Disease
Kano, K., Aoki, J., & Hla, T. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-050420-025929 · Cited by 164
Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
Jiang, D., Liang, J., Campanella, G. S., Guo, R., Yu, S., Xie, T., Liu, N., Jung, Y., Homer, R., Meltzer, E. B., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38644 · Cited by 159
Self-citationZhao, X., Cheng, Y., Cheng, M. L., Yu, L., Mu, M., Li, H., Liu, Y., Zhang, B., Yao, Y., Guo, H., et al. (2016) · Scientific Reports · doi:10.1038/srep19276 · Cited by 161
Shea, B. S., Brooks, S. F., Fontaine, B. A., Chun, J. J. M., Luster, A. D., & Tager, A. M. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0345oc · Cited by 155
Self-citationRafii, S., Cao, Z., Lis, R., Siempos, I. Ι., Chavez, D., Shido, K., Rabbany, S. Y., & Ding, B. (2015) · Nature Cell Biology · doi:10.1038/ncb3096 · Cited by 162
Sakai, N., Chun, J. J. M., Duffield, J. S., Wada, T., Luster, A. D., & Tager, A. M. (2013) · The FASEB Journal · doi:10.1096/fj.12-219378 · Cited by 163
“Including this study, data now implicate the LPA-LPA1 pathway in the development of lung (4), skin (5), kidney (6, 52), liver (53), and peritoneal fibrosis, suggesting that this pathway is of fundamental importance in the pathogenesis of fibrotic diseases associated with tissue injury.”
BackgroundMethodSelf-citationLipid Mediators in Life Science
Murakami, M. (2011) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.60.7 · Cited by 153
“pulmonary fibrosis [63, 77].”
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 154
Blaho, V. A., & Hla, T. (2011) · Chemical Reviews · doi:10.1021/cr200273u · Cited by 156
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A. L., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 162
Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA · doi:10.1001/jama.2023.5355 · Cited by 148
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt
Lim, J. H., Jono, H., Komatsu, K., Woo, C.-H., Lee, J., Miyata, M., Matsuno, T., Xu, X., Huang, Y., Zhang, W., et al. (2012) · Nature Communications · doi:10.1038/ncomms1776 · Cited by 149
Desroy, N., Housseman, C., Bock, X., Joncour, A., Bienvenu, N., Cherel, L., Labeguere, V., Rondet, E., Peixoto, C., Grassot, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00032 · Cited by 157
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Takuwa, N., Ohkura, S.-I., Takashima, S.-I., Ohtani, K., Okamoto, Y., Tanaka, T., Hirano, K., Usui, S., Wang, F., Du, W., et al. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp312 · Cited by 145
“These findings are consistent with the demonstration of other lysophospholipid receptors in fibrosis.(31) The relevance of these observations in transgenic mice to human cardiac fibrosis of the ischaemic, hypertensive, and other origins deserves further investigation.”
ResultSelf-citation
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.